Breast cancer and aneusomy 17: implications for carcinogenesis and therapeutic response

Monica M. Reinholz, Amy K. Bruzek, Daniel W Visscher, Wilma L. Lingle, Matthew J. Schroeder, Edith A. Perez, Robert Brian Jenkins

Research output: Contribution to journalArticle

79 Citations (Scopus)

Abstract

Abnormalities of chromosome 17, recognised over two decades ago to be important in tumorigenesis, often occur in breast cancer. Changes of specific loci on chromosome 17 including ERBB2 amplification, P53 loss, BRCA1 loss, and TOP2A amplification or deletion are known to have important roles in breast-cancer pathophysiology. Numerical aberrations of chromosome 17 are linked to breast-cancer initiation and progression, and possibly to treatment response. However, the clinical importance of chromosome 17 anomalies, in particular the effect on ERBB2 protein expression, is unknown. Reports are conflicting regarding the association of copy gain of chromosome 17 (polysomy 17) with strong ERBB2 protein expression in the absence of true ERBB2 gene amplification. Copy-number anomalies in chromosome 17 seem to be common in tumours that show discrepant ERBB2 expression and in tumours with discordant ERBB2-protein and ERBB2 gene copy number measurements. The mechanisms of ERBB2 dosage changes-gene amplification versus chromosome gain and loss-probably differ in primary and metastatic disease; however, a correction for chromosome 17 copy-number is necessary to completely distinguish between these mechanisms. A better understanding of how polysomy 17 affects gene-copy number and protein expression will help to select patients who will respond to therapies targeting ERBB2 and other protein products of chromosome 17 loci.

Original languageEnglish (US)
Pages (from-to)267-277
Number of pages11
JournalThe Lancet Oncology
Volume10
Issue number3
DOIs
StatePublished - Mar 2009

Fingerprint

Chromosomes, Human, Pair 17
Carcinogenesis
Breast Neoplasms
Gene Dosage
Gene Amplification
Therapeutics
Proteins
Neoplasms
Chromosomes

ASJC Scopus subject areas

  • Oncology

Cite this

Breast cancer and aneusomy 17 : implications for carcinogenesis and therapeutic response. / Reinholz, Monica M.; Bruzek, Amy K.; Visscher, Daniel W; Lingle, Wilma L.; Schroeder, Matthew J.; Perez, Edith A.; Jenkins, Robert Brian.

In: The Lancet Oncology, Vol. 10, No. 3, 03.2009, p. 267-277.

Research output: Contribution to journalArticle

Reinholz, Monica M. ; Bruzek, Amy K. ; Visscher, Daniel W ; Lingle, Wilma L. ; Schroeder, Matthew J. ; Perez, Edith A. ; Jenkins, Robert Brian. / Breast cancer and aneusomy 17 : implications for carcinogenesis and therapeutic response. In: The Lancet Oncology. 2009 ; Vol. 10, No. 3. pp. 267-277.
@article{d118c396e7eb49e4b52e3dd1c48b469d,
title = "Breast cancer and aneusomy 17: implications for carcinogenesis and therapeutic response",
abstract = "Abnormalities of chromosome 17, recognised over two decades ago to be important in tumorigenesis, often occur in breast cancer. Changes of specific loci on chromosome 17 including ERBB2 amplification, P53 loss, BRCA1 loss, and TOP2A amplification or deletion are known to have important roles in breast-cancer pathophysiology. Numerical aberrations of chromosome 17 are linked to breast-cancer initiation and progression, and possibly to treatment response. However, the clinical importance of chromosome 17 anomalies, in particular the effect on ERBB2 protein expression, is unknown. Reports are conflicting regarding the association of copy gain of chromosome 17 (polysomy 17) with strong ERBB2 protein expression in the absence of true ERBB2 gene amplification. Copy-number anomalies in chromosome 17 seem to be common in tumours that show discrepant ERBB2 expression and in tumours with discordant ERBB2-protein and ERBB2 gene copy number measurements. The mechanisms of ERBB2 dosage changes-gene amplification versus chromosome gain and loss-probably differ in primary and metastatic disease; however, a correction for chromosome 17 copy-number is necessary to completely distinguish between these mechanisms. A better understanding of how polysomy 17 affects gene-copy number and protein expression will help to select patients who will respond to therapies targeting ERBB2 and other protein products of chromosome 17 loci.",
author = "Reinholz, {Monica M.} and Bruzek, {Amy K.} and Visscher, {Daniel W} and Lingle, {Wilma L.} and Schroeder, {Matthew J.} and Perez, {Edith A.} and Jenkins, {Robert Brian}",
year = "2009",
month = "3",
doi = "10.1016/S1470-2045(09)70063-4",
language = "English (US)",
volume = "10",
pages = "267--277",
journal = "The Lancet Oncology",
issn = "1470-2045",
publisher = "Lancet Publishing Group",
number = "3",

}

TY - JOUR

T1 - Breast cancer and aneusomy 17

T2 - implications for carcinogenesis and therapeutic response

AU - Reinholz, Monica M.

AU - Bruzek, Amy K.

AU - Visscher, Daniel W

AU - Lingle, Wilma L.

AU - Schroeder, Matthew J.

AU - Perez, Edith A.

AU - Jenkins, Robert Brian

PY - 2009/3

Y1 - 2009/3

N2 - Abnormalities of chromosome 17, recognised over two decades ago to be important in tumorigenesis, often occur in breast cancer. Changes of specific loci on chromosome 17 including ERBB2 amplification, P53 loss, BRCA1 loss, and TOP2A amplification or deletion are known to have important roles in breast-cancer pathophysiology. Numerical aberrations of chromosome 17 are linked to breast-cancer initiation and progression, and possibly to treatment response. However, the clinical importance of chromosome 17 anomalies, in particular the effect on ERBB2 protein expression, is unknown. Reports are conflicting regarding the association of copy gain of chromosome 17 (polysomy 17) with strong ERBB2 protein expression in the absence of true ERBB2 gene amplification. Copy-number anomalies in chromosome 17 seem to be common in tumours that show discrepant ERBB2 expression and in tumours with discordant ERBB2-protein and ERBB2 gene copy number measurements. The mechanisms of ERBB2 dosage changes-gene amplification versus chromosome gain and loss-probably differ in primary and metastatic disease; however, a correction for chromosome 17 copy-number is necessary to completely distinguish between these mechanisms. A better understanding of how polysomy 17 affects gene-copy number and protein expression will help to select patients who will respond to therapies targeting ERBB2 and other protein products of chromosome 17 loci.

AB - Abnormalities of chromosome 17, recognised over two decades ago to be important in tumorigenesis, often occur in breast cancer. Changes of specific loci on chromosome 17 including ERBB2 amplification, P53 loss, BRCA1 loss, and TOP2A amplification or deletion are known to have important roles in breast-cancer pathophysiology. Numerical aberrations of chromosome 17 are linked to breast-cancer initiation and progression, and possibly to treatment response. However, the clinical importance of chromosome 17 anomalies, in particular the effect on ERBB2 protein expression, is unknown. Reports are conflicting regarding the association of copy gain of chromosome 17 (polysomy 17) with strong ERBB2 protein expression in the absence of true ERBB2 gene amplification. Copy-number anomalies in chromosome 17 seem to be common in tumours that show discrepant ERBB2 expression and in tumours with discordant ERBB2-protein and ERBB2 gene copy number measurements. The mechanisms of ERBB2 dosage changes-gene amplification versus chromosome gain and loss-probably differ in primary and metastatic disease; however, a correction for chromosome 17 copy-number is necessary to completely distinguish between these mechanisms. A better understanding of how polysomy 17 affects gene-copy number and protein expression will help to select patients who will respond to therapies targeting ERBB2 and other protein products of chromosome 17 loci.

UR - http://www.scopus.com/inward/record.url?scp=62849109983&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=62849109983&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(09)70063-4

DO - 10.1016/S1470-2045(09)70063-4

M3 - Article

C2 - 19261255

AN - SCOPUS:62849109983

VL - 10

SP - 267

EP - 277

JO - The Lancet Oncology

JF - The Lancet Oncology

SN - 1470-2045

IS - 3

ER -